Everything About CBD - What Is It? Complete Guide 2026

CBD, or cannabidiol, is one of the compounds produced by industrial hemp. It does not intoxicate, is not listed in Polish controlled substances schedules, and since 2018 has one registered medicinal form. However, so much marketing has grown around it that it is hard to separate what has been measured from what was invented for labeling purposes. This guide leads through the definition, mechanism of action, product forms, dosing, legal status, and principles of choosing oil. Behind every number here is work you can open and read, and where studies are lacking, it is stated plainly instead of softened with generalities. You will also see which popular statistics were removed from this text in editing and why none had a substitute. After reading, you will know what to realistically expect from cannabidiol.

KEY INFORMATION
• CBD does not stimulate the CB1 receptor like THC; in cell studies, it weakens the action of its agonists as a negative allosteric modulator (Laprairie 2015).
• The only measured absolute bioavailability of cannabidiol in humans concerns inhalation and is 31%; no such measurement exists for oral or sublingual routes (Millar 2018).
• A high-fat meal increased CBD exposure 4.85-fold in Cmax and 4.2-fold in AUC (Taylor 2018).
• The Polish 0.3% THC threshold in industrial hemp counts as the sum of delta-9-THC and THCA, not delta-9-THC alone.
• The only registered cannabidiol medicine covers exclusively drug-resistant epilepsies; other uses are unregistered.

What is CBD and where does it come from?

CBD, or cannabidiol, is a compound produced by industrial hemp Cannabis sativa L. It does not intoxicate because it does not stimulate the CB1 receptor like THC. In the living plant, it mainly occurs as the acidic form CBDA, and only heating converts it to the active form. Its molecular formula is the same as THC, C21H30O2, but with a different spatial arrangement.

The raw material for legal products is industrial hemp, i.e., varieties with low THC content. Their cultivation in Poland requires registration with the regional director of KOWR. Extract is obtained from dried flower heads and then diluted with a carrier oil, most often fractionated MCT coconut oil. Oil pressed from hemp seeds does not contain significant cannabidiol and is not the same product, although label names can be misleading.

The cannabidiol content in flower heads depends on the variety, harvest time, and drying method, so the only reliable number is from the certificate of analysis of a specific batch. The repeated advertising claim that cannabidiol constitutes 10-20% of flower mass has no source that can be opened and verified. We removed it from this text along with other unsupported numbers.

There are three extraction methods today. Supercritical carbon dioxide allows control of temperature and pressure and leaves no solvent after evaporation. Ethanol extraction is cheaper but requires careful alcohol evaporation. Hydrocarbon extraction yields the most concentrated extracts and the highest risk of residues. The method and solvent residue test results are found in the certificate of analysis. We described cannabidiol’s properties in detail in a separate guide to CBD properties.

It is worth noting the difference between CBDA and CBD, as it explains something surprising to beginners. Fresh herb mainly contains the acidic form and releases little of it when brewed in water because the acid dissolves poorly in fat. Only heating removes the carboxyl group and converts CBDA to CBD. Therefore, the same amount of herb behaves differently in a vaporizer, in an infusion, and in oil where the extract is already processed.

The law lists purposes for which industrial hemp may be cultivated, and the list is long: from textile to food uses. Thus, raw material from one plantation goes into products of completely different categories.

How does CBD differ from THC?

The difference is not in the molecular formula, which is identical, but in how each compound interacts with the CB1 receptor. THC stimulates it directly, causing intoxication. Cannabidiol behaves oppositely in cell studies: it weakens the strength and efficacy of CB1 agonists, acting as a negative allosteric modulator (Laprairie 2015).

The practical consequence is this: full-spectrum products contain trace THC within legal limits but may still be detected by sensitive tests with intensive daily use. Professionally tested individuals usually choose variants declaring zero THC content and confirm it with batch certificates. This is the only way to replace marketing claims with verifiable numbers.

Identical molecular formula with different effects is often treated as a curiosity but is the core issue. Whether a molecule stimulates the receptor depends on its spatial shape, i.e., the arrangement of the same atoms. The receptor recognizes geometry, not composition. Thus, two compounds with the same molecular weight can have vastly different effects, and copying the formula from packaging proves nothing.

The second difference concerns how both molecules behave together. Cannabidiol given with THC weakened the receptor’s response to the latter in cell studies. Therefore, full-spectrum extract is not a simple sum of components, and comparing it to isolate based on cannabidiol milligrams alone misses the point.

How does CBD act in the body?

Cannabidiol acts indirectly on the endocannabinoid system. This system consists of CB1 and CB2 receptors, endogenous cannabinoids mainly anandamide and 2-AG, and enzymes that produce and degrade them. It is a modulatory network, not a switch, tuning synaptic function and signaling in the developing brain (Lu and Mackie 2021).

Cannabidiol itself binds weakly to CB1 and CB2. Instead, it changes how the CB1 receptor responds to the body’s own messengers. This was confirmed in cell lines: cannabidiol presence reduced the efficacy and potency of 2-AG and THC and inhibited receptor internalization.

Beyond the endocannabinoid system, cannabidiol has several other molecular targets, including the serotonin 5-HT1A receptor, TRPV channels, and nuclear receptors of the PPAR family. However, a pharmacology review emphasizes that the number of possible targets does not replace clinical evidence, as most claimed benefits do not come from controlled studies (Britch 2021).

The popular explanation that cannabidiol raises anandamide levels by blocking FAAH enzyme is a hypothesis discussed in literature, not a consistently measured fact in humans. It is more honest in consumer texts to say that cannabidiol’s mechanism in humans is not yet fully understood. How cannabinoids distribute among these pathways is shown in the text about how cannabinoids act on the human body.

The two receptor types are distributed differently. CB1 is dense in the central nervous system and responsible for most psychoactive effects of THC. CB2 predominates in immune cells and peripheral tissues. The system’s messengers, anandamide and 2-AG, are produced on demand and act retrogradely, i.e., from the receiving neuron back to the sending one. This unusual direction explains why the endocannabinoid system functions as a tuning brake, not a transmitter.

This structure explains the caution in literature. Since the system affects sleep, appetite, pain perception, and inflammatory response simultaneously, a substance modulating it indirectly may produce diffuse effects hard to measure with a single indicator. Therefore, cannabidiol studies more often show moderate changes at many points than a single clear result.

What do clinical studies confirm about CBD?

The strongest data concern drug-resistant epilepsies, which led to medicine registration. Outside this area, evidence is much weaker: from small trials, case series, or cell studies. A cannabidiol pharmacology review states this plainly, noting that the only product subjected to full pharmacokinetic and clinical evaluation is the medicine registered for pediatric epilepsies (Britch 2021).

Shannon’s series is often cited as evidence for insomnia efficacy but is a chart review without a control group, with sleep results fluctuating over months. The authors conclude controlled studies are needed. This difference between observation and clinical trial is worth remembering with every advertisement.

The Dravet trial also shows the other side of the balance. Side effects were more frequent than placebo and included diarrhea, vomiting, fatigue, fever, drowsiness, and abnormal liver tests. More participants withdrew from cannabidiol than placebo. Efficacy and burden go hand in hand here, which is normal for a medicine and unusual for a supplement.

What are the forms of CBD products?

Form determines two things: how quickly the compound appears in blood and how precisely the dose can be measured. Other differences, including taste and convenience, are secondary. Market percentage splits circulating in articles come from sales reports unavailable for review, so we do not provide them here.

Oil remains the most controllable form because a graduated pipette allows doses below five milligrams and returning to them the next day. Gummies do not allow this, and cosmetics are not dosed forms at all. If you are just starting, begin with oil and add other forms once you know your effective dose.

In vaporization, temperature is decisive. Too low does not release cannabinoids; too high causes burning, producing smoke with decomposition products instead of vapor. Devices with ten-degree increments allow control; one-button devices do not. This is also the only administration route with measured absolute bioavailability in humans, so comparisons with oral forms are not symmetrical.

Cosmetics require special attention because their declarations are often vague. A sensible label states cannabidiol content in milligrams per package or per 100 grams. Phrases like “with hemp extract” say nothing, and hemp seed oil in ingredients is not the same as flower extract.

How much CBD really reaches the blood?

The answer is: for most forms, no one has measured this in humans. A systematic cannabidiol pharmacokinetic review searched 792 publications and found 24 with human data. Absolute bioavailability was reported only for inhalation, at 31%. No such measurement exists for other routes (Millar 2018).

This is important because a four-column table with values 6-15% oral, 13-19% sublingual, and 30-35% inhaled has circulated in Polish internet for years and appeared in previous versions of this post. No paper supports it that can be opened. We removed it instead of correcting because no correct version exists.

The same review provides other measured numbers: half-life from 1.4 to 10.9 hours after mucosal aerosol, 2 to 5 days with chronic oral dosing, and 31 hours after inhalation. Time to maximum concentration ranges from zero to four hours, and maximum concentration increases with food and fat formulations.

The scale of the latter was measured separately. In a phase 1 study, a high-fat meal increased maximum cannabidiol concentration 4.85-fold and area under the curve 4.2-fold, with unchanged time to peak (Taylor 2018). The practical takeaway: take oil with food and always the same way, or you compare incomparable days.

The same study provides data on accumulation. With twice-daily dosing, steady state was reached after about two days, and concentration increased 1.8 to 2.6 times. The terminal half-life was about 60 hours, while the effective half-life was 10 to 17 hours. The first describes residual elimination, the second the daily dosing rhythm.

This explains the advice to start assessment only after several days of regular use. The first dose does not yet show the level at which the body stabilizes. The same mechanism explains why a break of several days and return to the same dose feels different than continuous use.

How to dose CBD?

No reference dose for non-medical use has been established, and no source provides one. The only numbers with coverage are doses used in specific studies linked to specific endpoints. The table below collects them to show how much they differ and how little they relate to package suggested portions.

From the two anxiety trials comes a counterintuitive conclusion: the dose-effect relationship is an inverted U shape. The middle dose worked, not the highest. So if a portion does not bring change, simply increasing it may not help and can be a step backward.

Practically, this means three things. Start with a small portion and change it no more often than every few days. Record the dose with time and meal, as without this you cannot distinguish product effect from day of the week. Stick to one product during the trial because changing concentration also changes the oil matrix.

There is also a pharmacokinetic reason why increasing dose fails. In a dose-escalation study, exposure increased slower than dose: doubling amount raised maximum concentration and area under curve less than twofold. Doubling dose does not mean doubling blood levels. It means doubling cost and higher risk of dose-dependent side effects.

Is CBD legal in Poland in 2026?

Yes. Cannabidiol is not listed in any schedules of psychotropic substances, narcotics, or new psychoactive substances. The word “cannabidiol” does not appear in the Regulation of the Minister of Health of August 17, 2018 (consolidated text Dz.U. 2024 item 1139). Products from industrial hemp are legal if they meet the THC content threshold.

The threshold is defined by Article 4 point 5 of the Act on Counteracting Drug Addiction (consolidated text Dz.U. 2023 item 1939), as amended by the Act of March 24, 2022 (Dz.U. 2022 item 763). Industrial hemp plants have a sum of delta-9-THC and tetrahydrocannabinolic acid in flower or fruiting tops not exceeding 0.3% dry weight, rounded to one decimal place.

This distinction changes lab test results and is not a formality. The threshold concerns the sum, not delta-9-THC alone. Until May 6, 2022, the value was 0.20%, and from May 7, 2022, it is 0.3%; statements about 0.2% threshold are now only correct as historical facts with dates.

The EU threshold has the same value but a separate basis: Article 4 paragraph 4 of Regulation 2021/2115, effective from January 1, 2023. Previously it was 0.2% under repealed Regulation 1307/2013. The correct phrasing is that the national threshold corresponds to the EU one, not that it derives from it. Also remember cannabinoids remain under the EU novel food procedure, so edible products are sold in Poland outside the dietary supplement category.

Hemp seed food has separate limits expressed in milligrams per kilogram, not percentages. For seeds and processed products, the maximum allowed level is 3.0 mg/kg, and for seed oil 7.5 mg/kg. The level refers to the sum of delta-9-THC and THCA expressed as delta-9-THC. The basis is Annex I to Commission Regulation 2023/915, effective May 25, 2023. Confusing these limits with the 0.3% threshold is the most common mistake in culinary hemp texts.

Finally, a distinction readers ask about most often. Cannabidiol is not a controlled substance, but HHC, hexahydrocannabinol, is. These are two different legal statuses, and no schedule changes have reversed this. If a seller places both compounds as equally legal, it signals they have not checked the legal status.

How to choose a good CBD product?

One thing decides: a certificate of analysis issued by an independent laboratory for the batch you hold. Without it, you do not know how much cannabidiol is in the bottle or what else it contains. Price and declared concentration do not replace this document, as both numbers are set by the seller, not the lab.

• The batch number on the label must be found in the certificate; a “template” certificate for the whole product line confirms nothing.
• The certificate should include cannabinoid contents, tests for heavy metals, pesticides, solvent residues, and microbiological contamination.
• The test date should be close to the batch production date, not from years ago.
• The extraction method is sometimes described in the certificate and allows verifying the seller’s claim.

The second decision concerns extract type. Isolate is purified cannabidiol without other plant components. Broad spectrum contains other cannabinoids and terpenes but no THC. Full spectrum preserves natural proportions including trace THC within legal limits. The choice mainly depends on whether you are subject to drug testing.

The entourage effect, i.e., the hypothesis that plant components enhance each other, remains a hypothesis discussed in reviews, not a measured quantity. Numbers like “30-40% stronger than isolate” come from no study and were removed from this text. If a seller gives such a value, ask for the source paper.

Also pay attention to the relation between declaration and measurement. The percentage on the bottle is the producer’s claim, and the certificate shows the result for a specific batch. These two numbers may differ within analytical tolerance, but a discrepancy of tens of percent is not normal. Comparing takes a minute and is the only way to check if you pay for milligrams or for a label.

What are CBD side effects and interactions?

Cannabidiol is usually well tolerated but not inert. A clinical data review indicates the most common side effects are fatigue, diarrhea, and changes in appetite and body weight, noting this profile compares favorably to drugs used for the same indications (Iffland and Grotenhermen 2017).

A phase 1 dose-escalation study gave a similar picture. Most common events were diarrhea, nausea, headache, and drowsiness, all mild or moderate, with no severe cases or study discontinuations due to side effects.

A separate review including consumer use is more cautious. It reports nearly half of users experienced side effects, dose-dependent, including increased aminotransferase activity, drowsiness, sleep disturbances, infections, and anemia (Brown and Winterstein 2019).

The same review describes drug interaction mechanisms. Cannabidiol affects CYP3A4 and CYP2C19 enzymes and P-glycoprotein responsible for drug elimination, so the risk of interactions with commonly used drugs is high. Authors recommend considering lower primary drug dose, monitoring side effects, or alternative therapy. If you take chronic medications, decide on combining with cannabidiol with your doctor or pharmacist, not the seller.

The liver deserves a separate note. Increased aminotransferase activity appears in registration studies and consumer use reviews. In the Dravet trial, abnormal liver tests were more frequent with cannabidiol than placebo. People with liver disease should treat cannabidiol as a substance requiring supervision, not a neutral dietary additive.

A common mistake is assuming that because something is plant-based, it does not interact. The mechanism described above works exactly as with synthetic drugs: inhibited enzyme breaks down the other drug more slowly, raising its concentration. Highest caution is needed with drugs with narrow therapeutic windows, where small concentration changes alter effect.

How to start using CBD step by step?

The scheme below is a way to organize your own trial, not medical advice. Its point is to have a basis for decision after six weeks instead of impressions. Change only one thing at a time, as two changes at once make it impossible to tell what worked.

• Weeks 1 and 2: small portion once daily, at a fixed time, always with a fat-containing meal. Record sleep, tension, and mood in a 1-10 scale each morning.
• Weeks 3 and 4: if no change, increase dose by one step and keep for two weeks. If daytime drowsiness appears, move the entire dose to evening instead of increasing.
• Weeks 5 and 6: maintain effective dose and do not increase further. If no change, consider another form or stopping rather than further increase.
• After completion: compare notes from first and last week. Without this, you rely only on memory, which systematically errs in such trials.

If unexplained symptoms appear, stop and consult a doctor. This especially concerns people taking drugs metabolized by CYP3A4 and those with liver diseases, as the liver processes cannabidiol and shows first deviations in tests.

The scheme has another less obvious function. It sets the moment when you can say “it does not work” and end the trial without feeling impatience. Without such a limit, it is easy to keep increasing dose, which with an inverted U shape can be a step backward. Six weeks is arbitrary but sufficient to pass steady state and collect data from several comparable days.

Frequently Asked Questions

What is CBD in the simplest terms?

Cannabidiol is a compound from industrial hemp that does not intoxicate. It does not stimulate the CB1 receptor like THC but changes how this receptor responds to the body’s own messengers (Laprairie 2015). Beyond the endocannabinoid system, it has been described to have several other molecular targets, but the translation of this to clinical effect remains poorly documented.

Is CBD legal in Poland in 2026?

Yes. Cannabidiol is not listed in any controlled substances schedules, and products from industrial hemp are legal as long as the sum of delta-9-THC and THCA does not exceed 0.3% of dry weight. The basis is Article 4 point 5 of the Act on Counteracting Drug Addiction as effective from May 7, 2022.

How quickly does CBD act after administration?

After an oral dose, blood concentration peaks after about 4-5 hours (Taylor 2018). A pharmacokinetic review reports time to maximum concentration ranging from zero to four hours depending on the route of administration, with inhalation being the fastest (Millar 2018). Subjective sensation may occur earlier than peak concentration.

What CBD doses were used in studies?

In trials on public speaking anxiety, a single 300 mg dose was effective, while 150 mg, 600 mg, and 900 mg doses did not differ from placebo. In drug-resistant epilepsy, 20 mg per kilogram of body weight daily was used under medical supervision. No reference dose for non-medical use has been established.

Does CBD cause addiction or intoxication?

It does not intoxicate because it does not stimulate the CB1 receptor as THC does. No signals of addiction potential have been described, and a review of clinical data indicates the most common side effects are fatigue, diarrhea, and changes in appetite and body weight (Iffland and Grotenhermen 2017). This is a mild but not zero profile.

How to choose a good CBD oil?

Check the certificate of analysis for the batch number on the label, not a generic certificate for the entire product line. It should provide cannabinoid contents and test results for heavy metals, pesticides, and solvent residues. Forms mainly differ in dosing precision, so it is easier to control oil drops than gummies at the start.

Does CBD interact with medications?

Yes. Cannabidiol affects CYP3A4 and CYP2C19 enzymes and P-glycoprotein, so the risk of interactions with commonly used drugs is high (Brown and Winterstein 2019). Review authors recommend considering a lower dose of the primary drug or alternative therapy. Decide on combining with your doctor or pharmacist.

Is CBD safe for children and during pregnancy?

There is no data to consider use during pregnancy and breastfeeding safe, so it is not recommended. In children, the only approved and controlled use is for drug-resistant epilepsies, including Dravet syndrome, conducted exclusively under medical supervision.

Summary

Cannabidiol is a compound with a mild safety profile and a narrow but strong evidence base. The strong part concerns drug-resistant epilepsies and individual trials on situational anxiety. Everything else relies on case series, cell studies, or nothing verifiable.

All second- and third-category numbers disappeared from this editorial: bioavailability tables without sources, market percentages from unavailable reports, customer satisfaction rates, and values describing entourage effect strength. Only verifiable numbers and statements about what was not measured remain. We continue expanding the Q&A set in the CBD questions collection.

If you start, reduce the decision to three steps. Choose a product with a certificate of analysis for the correct batch. Start with a small portion taken with a fatty meal at a fixed time. Give yourself several weeks and record effects instead of relying on memory. With chronic medications, consult your doctor or pharmacist first.

You can find industrial hemp oils with batch certificates in the oils category at u Bucha store.

This article is informational and educational and does not constitute medical advice. Before starting hemp or CBD for therapeutic purposes, consult a doctor, especially if you take other medications, are pregnant, or breastfeeding.

Author: Michał Waluk · Published: 2026-05-04 · Updated: 2026-08-10